Adding L-Carnitine to Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovary Syndrome
NCT ID: NCT03630341
Last Updated: 2018-08-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
150 participants
INTERVENTIONAL
2016-02-01
2018-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
L-Carnitine and Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovary Syndrome
NCT03476356
Ovulation Induction in Clomiphene Citrate Resistant PCO Women
NCT02341703
Adding L-carnitine in Clomiphene Resistant Polycystic Ovary Improves the Quality of Ovulation and the Pregnancy Outcome
NCT01665547
The Effects of Acetyl-L-Carnitine and Myo/Chiro-Inositol in Patients With PCOS
NCT05767515
Safety of Hormonal Contraceptives Therapies in Polycystic Ovary Syndrome (PCOS) Women
NCT00842140
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
study group
This group will receive oral clomiphene citrate 50 mg tablet, two times per day from the third day of the cycle until the seventh day of the cycle plus oral carnitine 1g tablet, three times per day from the third day until the day of the pregnancy test.
Clomiphene Citrate 50mg
oral 50 mg tablets
L-carnitine
1000 mg oral tablet
control group
This group will receive oral clomiphene citrate 50 mg tablet, two times per day from the third day of the cycle until the seventh day of the cycle plus oral placebo tablet, three times per day from the third day until the day of the pregnancy test.
Clomiphene Citrate 50mg
oral 50 mg tablets
Placebo Oral Tablet
oral tablets identical to L-carnitine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Clomiphene Citrate 50mg
oral 50 mg tablets
L-carnitine
1000 mg oral tablet
Placebo Oral Tablet
oral tablets identical to L-carnitine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Normal Hysterosalpingo-graphy
* Normal Semen analysis of the husband.
Exclusion Criteria
* Male factors of infertility and/or abnormal Hysterosalpingo-graphy
* Hyperprolactinemia (prolactin ≥ 22 ng/dl).
* FSH on day 3 \> 15 mIU/mL.
* Gross ovarian pathology diagnosed by ultrasound.
18 Years
35 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed Mohamed Abbas
Principal investigator
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LCCC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.